Bhavana Bhatnagar, DO
Hematology & Oncology · Wheeling, WVNPI 1154598498
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $53,754 of the $71,710 with a category attached, or 75.0%. It is spread thinly across 22 manufacturers, the largest accounting for just 14.6%. Among hematology & oncology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $731.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$10K
- Novartis$9K
- E.r. Squibb & Sons, L.L.C.$9K
- Daiichi Sankyo Inc.$9K
- Gilead$8K
- AstraZeneca$7K
- plus $19K from 16 others
Across 65 payments — averaging $6910.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$173K
- Novartis$90K
- Otsuka Pharmaceutical Co., Ltd.$78K
- Epizyme, Inc.$32K
- Genentech, Inc.$26K
- E.r. Squibb & Sons, L.L.C.$23K
- plus $28K from 2 others
What the payments were for
- Consulting fees$53,75475%
- Speaking & faculty fees$10,01014%
- Travel & lodging$5,4448%
- Food & beverage$1,9973%
- Education$5061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 15 | $10,489 |
| Novartis | 6 | $9,393 |
| E.r. Squibb & Sons, L.L.C. | 5 | $9,100 |
| Daiichi Sankyo Inc. | 7 | $8,603 |
| Gilead | 6 | $8,086 |
| AstraZeneca | 14 | $6,684 |
| Astellas Pharma Global Development | 6 | $6,310 |
| Syndax Pharmaceuticals, Inc. | 7 | $5,250 |
| Pfizer | 3 | $3,607 |
| Karyopharm Therapeutics Inc. | 14 | $3,035 |
| AbbVie | 2 | $224 |
| Astellas Pharma US Inc | 2 | $173 |
| Epizyme, Inc. | 1 | $165 |
| Taiho Oncology, Inc. | 1 | $138 |
| Incyte Corporation | 1 | $96 |
| Bristol Myers Squibb | 1 | $89 |
| Beigene USA, Inc. | 2 | $67 |
| Adaptive Biotechnologies Corporation | 1 | $64 |
| Johnson & Johnson | 1 | $41 |
| Rigel Pharmaceuticals, Inc. | 1 | $37 |
| Caris MPI, Inc. | 1 | $33 |
| Tempus AI, Inc | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,710 in reported general payments places this provider in the 90th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 50 | $609,606 |
| RevlimidLenalidomide | 34 | $593,900 |
| Lenalidomide | 46 | $567,547 |
| PomalystPomalidomide | 26 | $458,686 |
| JakafiRuxolitinib Phosphate | 16 | $243,594 |
| BosulifBosutinib | 12 | $121,384 |
| Imatinib Mesylate | 28 | $33,395 |
| EliquisApixaban | 25 | $15,239 |
| Ondansetron Hcl | 37 | $3,821 |
| Hydroxyurea | 50 | $1,348 |
| Acyclovir | 86 | $1,149 |
| Anastrozole | 43 | $860 |
| Oxycodone Hcl | 42 | $665 |
| Fluconazole | 19 | $600 |
| Dexamethasone | 29 | $559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $6,684 | $609,60650 claims |
| Bristol Myers SquibbRevlimid | $89 | $593,90034 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $9,100 | $458,68626 claims |
| Incyte CorporationJakafi | $96 | $243,59416 claims |
| PfizerBosulif, Eliquis | $3,607 | $136,62337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Wheeling
- Anup DasWheeling$3K
- Gurveen KaurWheeling$127
- Chandana KamireddyWheeling$116
- Damian SilberminsHuntington$277K
- Abraham KanateMorgantown$169K
- Salman OsmanBridgeport$118K
- Ashkan EmadiMorgantown$88K
- Konstantinos SdrimasMorgantown$81K
- Arvinder BirHuntington$74K
- Ihtishaam QaziMorgantown$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.